Unlocking an Affordable Future: Key #1 Ensure System Sustainability ENSURE SYSTEM SUSTAINABILITY BY PROMOTING COMPETITION A competitive private market is the best way to manage drug costs. Interventions should be focused on fixing specific market failures or gaps rather than
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. All that Glitters is Not Gold… It’s true,
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market and have advocated for policy changes that will increase generic and biosimilar uptake and put an end to brand manufacturers’ tactics to extend exclusivity on brand-name biologics. As more
In case you missed it, Johnny Garcia, PharmD, Senior Director, Policy at the Pharmaceutical Care Management Association (PCMA), explains the critical role pharmacy benefit companies play in supporting all members of the prescription drug supply chain, including retail pharmacies, in
Bass Explains Opposition to Legislation, Risk of Drug Companies Lowering Rx Discounts On Wednesday, expert witnesses testifying before the U.S. House Committee on Energy & Commerce Subcommittee on Health highlighted the critical value pharmacy benefit companies provide for patients, employers, and
In case you missed it, a new PCMA Rx Research Corner blog highlighted the value employers find in their pharmacy benefit company relationships. As Congress considers passing misguided proposals in the new year that will undermine the critical flexibility and
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. For Prescriptions It’s Home Sweet Home for Patients…
In case you missed it, last week’s RealClearPolitics’ virtual event, “The Consequences of Targeting Pharmacy Benefits,” featured policymakers and expert voices exploring the potential negative impact of policies being considered by Congress that target pharmacy benefit companies and market-based incentives
©2024 PCMA. All Rights Reserved.
